Table 1.
Pharmacological characteristics of WT GluR3 and the GFP-tagged variants
| Agonist/antagonist | WT GluR3 | GFP-GluR3 | GluR3-GFP |
|---|---|---|---|
| Kainate | |||
| EC50 | 87 ± 6 (6) | 129 ± 18 (4) | 122 ± 14 (9) |
| nH | 3 ± 0.2* | 1.2 ± 0.1* | 1.7 ± 0.1* |
| Glutamate | |||
| EC50 | 10 ± 3 (4) | 10 ± 2 (6) | 78 ± 22 (5)* |
| nH | 0.8 ± 0.1 | 1.1 ± 0.2 | 0.8 ± 0.1 |
| AMPA | |||
| EC50 | 0.67 ± 0.2 (9) | 0.53 ± 0.04 (3) | 6.09 ± 1.2 (9)* |
| nH | 1.3 ± 0.1 | 1.3 ± 0.2 | 1.8 ± 0.03* |
| NBQX (IC50) | 65 ± 12·10−3 (3) | 56 ± 12·10−3 (4) | 59 ± 15·10−3 (4) |
| CNQX (IC50) | 0.49 ± 0.33 (5) | 0.52 ± 0.31 (5) | 0.43 ± 0.6 (4) |
EC50 in μM. Values shown are mean ± SEM. Oocytes were obtained from at least three different donors and injected with at least three different preparations of cRNAs. Number in parentheses is the number of oocytes tested. AMPA was coapplied with CTZ. nH, slope coefficient. *, P < 0.05.